Maroto, P, Porta, C, Capdevila, J, Apolo, AB, Viteri, S, Rodriguez-Antona, C, Martin, L, Castellano, D. Cabozantinib for the treatment of solid tumors: a systematic review. Therapeutic Advances in Medical Oncology. 2022; 14DOI:10.1177/17588359221107112. PMID:35847482. IF:4.900(Q2/4D).

Castellano, D, Apolo, AB, Porta, C, Capdevila, J, Viteri, S, Rodriguez-Antona, C, Martin, L, Maroto, P. Cabozantinib combination therapy for the treatment of solid tumors: a systematic review. Therapeutic Advances in Medical Oncology. 2022; 14DOI:10.1177/17588359221108691. PMID:35923927. IF:4.900(Q2/4D).

Chow, LQM, Barlesi, F, Bertino, EM, van den Bent, MJ, Wakelee, HA, Wen, PY, Chiu, CH, Orlov, S, Chiari, R, Majem, M, McKeage, M, Yu, CJ, Garrido, P, Hurtado, FK, Arratia, PC, Song, YB, Branle, F, Shi, M, Kim, DW. ASCEND-7: Efficacy and Safety of Ceritinib Treatment in Patients with ALK-Positive Non-Small Cell Lung Cancer Metastatic to the Brain and/or Leptomeninges. CLINICAL CANCER RESEARCH. 2022; 28(12)DOI:10.1158/1078-0432.CCR-21-1838. PMID:35091443. IF:11.500(Q1/1D).

Majem, M, Goldman, JW, John, T, Grohe, C, Laktionov, K, Kim, SW, Kato, T, Vu, HV, Lu, S, Li, SQ, Lee, KY, Akewanlop, C, Yu, CJ, de Marinis, F, Bonanno, L, Domine, M, Shepherd, FA, Atagi, S, Zeng, LM, Kulkarni, D, Medic, N, Tsuboi, M, Herbst, RS, Wu, YL. Health-Related Quality of Life Outcomes in Patients with Resected Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer Who Received Adjuvant Osimertinib in the Phase III ADAURA Trial. CLINICAL CANCER RESEARCH. 2022; 28(11)DOI:10.1158/1078-0432.CCR-21-3530. PMID:35012927. IF:11.500(Q1/1D).